BRPI0508560A - uso de antagonistas do receptor cb1 para a produção de uma composição útil para o tratamento de doenças hepáticas - Google Patents

uso de antagonistas do receptor cb1 para a produção de uma composição útil para o tratamento de doenças hepáticas

Info

Publication number
BRPI0508560A
BRPI0508560A BRPI0508560-8A BRPI0508560A BRPI0508560A BR PI0508560 A BRPI0508560 A BR PI0508560A BR PI0508560 A BRPI0508560 A BR PI0508560A BR PI0508560 A BRPI0508560 A BR PI0508560A
Authority
BR
Brazil
Prior art keywords
treatment
receptor antagonists
liver disease
produce
composition useful
Prior art date
Application number
BRPI0508560-8A
Other languages
English (en)
Inventor
Sophie Lotersztajn
Ariane Mallat
Pascale Grenard
Boris Julien
Jeanne Tran Van Nhieu
Original Assignee
Inst Nat Sante Rech Med
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Sanofi Aventis filed Critical Inst Nat Sante Rech Med
Publication of BRPI0508560A publication Critical patent/BRPI0508560A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE ANTAGONISTAS DO RECEPTOR CB1 PARA A PRODUçãO DE UMA COMPOSIçãO úTIL PARA O TRATAMENTO DE DOENçAS HEPáTICAS.A presente invenção refere-se ao uso de antagonistas para o receptor CB1 para o preparo de uma composição para o tratamento de doenças hepáticas e preferivelmente ao uso de N-piperidinos5 5-(4-clorofenil)-1-(2,4-diclorofenil)-4 metilpirazol-3-carboximida.
BRPI0508560-8A 2004-03-09 2005-03-08 uso de antagonistas do receptor cb1 para a produção de uma composição útil para o tratamento de doenças hepáticas BRPI0508560A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290633A EP1574211A1 (en) 2004-03-09 2004-03-09 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
PCT/EP2005/003285 WO2005084652A2 (en) 2004-03-09 2005-03-08 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

Publications (1)

Publication Number Publication Date
BRPI0508560A true BRPI0508560A (pt) 2007-08-14

Family

ID=34814417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508560-8A BRPI0508560A (pt) 2004-03-09 2005-03-08 uso de antagonistas do receptor cb1 para a produção de uma composição útil para o tratamento de doenças hepáticas

Country Status (27)

Country Link
US (2) US8236763B2 (pt)
EP (3) EP1574211A1 (pt)
JP (1) JP2007527893A (pt)
KR (1) KR20070026415A (pt)
CN (1) CN1929828A (pt)
AR (1) AR048087A1 (pt)
AT (1) ATE520393T1 (pt)
AU (1) AU2005218937B2 (pt)
BR (1) BRPI0508560A (pt)
CA (1) CA2557976A1 (pt)
CY (1) CY1112078T1 (pt)
DK (1) DK1725223T3 (pt)
ES (1) ES2371552T3 (pt)
HK (1) HK1094674A1 (pt)
IL (1) IL177465A0 (pt)
MA (1) MA28454B1 (pt)
MX (1) MXPA06010287A (pt)
NO (1) NO20064603L (pt)
PL (1) PL1725223T3 (pt)
PT (1) PT1725223E (pt)
RU (1) RU2402328C2 (pt)
SI (1) SI1725223T1 (pt)
TN (1) TNSN06272A1 (pt)
TW (1) TWI337540B (pt)
UA (1) UA94025C2 (pt)
WO (1) WO2005084652A2 (pt)
ZA (1) ZA200607159B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
EP2919779B1 (en) 2012-11-13 2021-01-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid receptor mediating compounds
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
PE20170258A1 (es) 2014-03-27 2017-03-23 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
AU2015255765A1 (en) 2014-05-09 2016-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
WO2017058771A1 (en) 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) recetor
WO2017184412A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
AT394493B (de) * 1989-05-11 1992-04-10 Homosan Ag Pharmazeutisches praeparat zur behandlung von lebererkrankungen
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US6143752A (en) * 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US6465436B2 (en) * 2000-06-01 2002-10-15 Mclean Hospital Method for treating alcohol intoxication and alcohol abuse
EE200300019A (et) * 2000-07-11 2004-10-15 Bayer Aktiengesellschaft Parapoxvirus ovis tüvede kasutamine organite fibrooside vastu
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
US20050154202A1 (en) * 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US20040034968A1 (en) * 2002-06-14 2004-02-26 Hufcor, Inc. 360 Degree hinge and door closure apparatus
SE0202242D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Compounds
SE0202240D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Genes
ATE375349T1 (de) * 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
FR2849032B1 (fr) * 2002-12-23 2006-04-28 Sanofi Synthelabo Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
CN1867332A (zh) * 2003-10-24 2006-11-22 索尔瓦药物有限公司 包含选择性cb1－拮抗剂和脂肪酶抑制剂的肥胖症的联合治疗
FR2861303A1 (fr) 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
GB0403780D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
TW200534851A (en) 2005-11-01
US8604060B2 (en) 2013-12-10
IL177465A0 (en) 2007-07-04
JP2007527893A (ja) 2007-10-04
CA2557976A1 (en) 2005-09-15
AU2005218937B2 (en) 2011-07-07
SI1725223T1 (sl) 2012-01-31
NO20064603L (no) 2006-10-09
UA94025C2 (ru) 2011-04-11
US8236763B2 (en) 2012-08-07
AR048087A1 (es) 2006-03-29
WO2005084652A2 (en) 2005-09-15
EP2305220A3 (en) 2011-05-18
PL1725223T3 (pl) 2012-01-31
EP1574211A1 (en) 2005-09-14
CY1112078T1 (el) 2015-11-04
EP2305220B1 (en) 2014-07-30
EP1725223B1 (en) 2011-08-17
EP1725223A2 (en) 2006-11-29
CN1929828A (zh) 2007-03-14
HK1094674A1 (en) 2007-05-18
KR20070026415A (ko) 2007-03-08
AU2005218937A1 (en) 2005-09-15
RU2006134707A (ru) 2008-04-20
US20080214449A1 (en) 2008-09-04
DK1725223T3 (da) 2011-11-28
PT1725223E (pt) 2011-12-02
EP2305220A2 (en) 2011-04-06
ATE520393T1 (de) 2011-09-15
ZA200607159B (en) 2008-02-27
ES2371552T3 (es) 2012-01-05
WO2005084652A3 (en) 2005-12-08
RU2402328C2 (ru) 2010-10-27
MXPA06010287A (es) 2007-02-14
US20120329833A1 (en) 2012-12-27
TNSN06272A1 (en) 2007-12-03
MA28454B1 (fr) 2007-03-01
TWI337540B (en) 2011-02-21

Similar Documents

Publication Publication Date Title
BRPI0508560A (pt) uso de antagonistas do receptor cb1 para a produção de uma composição útil para o tratamento de doenças hepáticas
ATE402697T1 (de) 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA29088B1 (fr) Composes d'indazole-carboxamide.
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
CL2008000369A1 (es) Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas.
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
TW200607491A (en) Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
JP2007520565A5 (pt)
RS54398B1 (en) THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
GT200500309A (es) Derivados de sulfonilbencilimidazol
WO2005121778A3 (en) Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
WO2007017126A3 (en) POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
EA200870074A1 (ru) Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
EA201000926A1 (ru) Пиперазины в качестве агентов против ожирения
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
GT200600296A (es) Derivados de n-[(1,5-fenil-1h-pirazol-3-il)-metil] sulfonamida, su preparación y su aplicación en terapeutica
ES2331278A1 (es) Polimorfo gamma de una pirazolina sustituida, su preparacion y su uso como medicamento.
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento
BRPI0607894A2 (pt) utilização de um derivado de pirazol para a preparação de medicamentos úteis na prevenção e no tratamento das doenças renais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.